Clinical trials: Vascular And Immunologic Diseases
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
- Trial name
- NCT06515262
- Testing
- Anti-BCMA-GPRC5D CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
- Conditions
- Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT04662294
- Testing
- CD70 CAR T-cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
This is an open-label, non-randomized Phase 1 study evaluating the role of two regimens: A) Nivolumab in combination with Pomalidomide and low dose dexamethasone and B) Nivolumab + Elotuzumab + Pomalidomide + dexamethasone in the…
- Trial name
- NCT03023527
- Testing
- Nivolumab, Pomalidomide, Dexamethasone
- Where
- 12 sites in Spain
- Volunteers
- 6 people
- Sponsor
- PETHEMA Foundation
ANCA Associated Vasculitis, Microscopic Polyangiitis
Hydroxychloroquine in ANCA Vasculitis Evaluation
The purpose of this study is to find out whether hydroxychloroquine, in addition to background treatments, reduces disease activity in patients with Anti-Neutrophilic Cytoplasmic Autoantibodies (ANCA) Vasculitis, a group of…
- Conditions
- ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis
- Trial name
- HAVEN (NCT04316494)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT06592222
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Chronic Urticaria
Stress Intervention for Chronic Urticaria
Stress and chronic urticaria has been linked. The purpose of the study is to evaluate a patients chronic urticaria and stress levels before and after he/she goes through six sessions designed to help that participant manage…
- Trial name
- NCT01111136
- Testing
- Stress intervention
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Mississippi Medical Center
Multiple Myeloma
GMMG-HD11/DSMM XXI/64007957MMY3010
This is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE…
- Trial name
- AugMMent (NCT07671287)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Volunteers
- 399 people
- Sponsor
- University of Heidelberg Medical Center
Multiple Myeloma
Finistere Myeloma Observatory (OMYFIN)
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict prognosis.
- Trial name
- OMYFIN (NCT06552221)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
To identify the maximum tolerated dose (MTD) of oral azacitidine on different treatment schedules in Japanese subjects with hematological neoplasms
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01908387
- Testing
- Oral azacitidine
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Celgene Corporation
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT.
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT01402687
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Dana-Farber Cancer Institute
HIV Infection, Alcohol Use
Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)
This study is a randomized controlled trial (RCT) to compare the effects of varenicline, cytisine, and nicotine replacement therapy (NRT) to reduce: 1) alcohol use and craving, 2) smoking; and 3) inflammation and risk for…
- Conditions
- HIV Infection, Alcohol Use, Smoking
- Trial name
- St PETER HIV (NCT02797587)
- Testing
- Varenicline, Cytisine, Nicotine Replacement Therapy
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- Boston Medical Center
Multiple Myeloma
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to…
- Trial name
- Talisman (NCT06500884)
- Testing
- Talquetamab, Prophylaxis A, Prophylaxis B
- Where
- 38 sites in United States, Brazil and 5 more
- Volunteers
- 210 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse…
- Trial name
- NCT00396045
- Testing
- Revlimid (CC-5013)
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- University of Turin, Italy
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Large Vessel Vasculitis, Takayasu Arteritis
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are…
- Conditions
- Large Vessel Vasculitis, Takayasu Arteritis, Giant Cell Arteritis (GCA)
- Trial name
- LAVA-FLOW (NCT07628075)
- Testing
- [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Waldenstrom Macroglobulinemia
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Current therapies for Recurrent or Refractory Waldenstrom's Macroglobulinemia provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment…
- Trial name
- NCT00003512
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Sponsor
- Burzynski Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.